Chapter 17 — Further Reading

Sources are grouped by the book's three citation tiers (see the style bible): Tier 1 is verified and canonical; Tier 2 is real practice or material attributed honestly without a pinned-down citation; and Tier 3 is the constructed teaching material in this chapter. Read critically, and remember that insurer-specific underwriting manuals and rate tables are proprietary — what follows points to public and educational sources, not to any carrier's confidential plan.

Tier 1 — Verified canonical

  • Genetic Information Nondiscrimination Act (GINA) of 2008 — the U.S. federal statute restricting use of genetic information; note its strong reach into health insurance and employment and its limited reach into life, disability, and long-term-care underwriting (the "genetics gap" of §17.7).
  • Fair Credit Reporting Act (FCRA) — governs consumer-report data used in underwriting (the MVR, certain database reports) and imposes the adverse-action notice obligation referenced throughout §17.2 and §17.7. (Owned by Chapter 4; central to this chapter's compliance line.)
  • National Association of Insurance Commissioners (NAIC) — the standard-setting body for U.S. state insurance regulation; its model bulletin on insurers' use of artificial intelligence and its work on accelerated underwriting and big data are the live regulatory backdrop for §17.7 and Case Study 1.
  • The Institutes (AINS / CPCU curricula) and the SOA/Academy of Actuaries materials — the professional bodies whose public-facing educational content covers mortality, risk classification, and life underwriting fundamentals tested in §17.2–§17.5.

Tier 2 — Real practice, attributed honestly

  • Life impairment manuals and reinsurer underwriting guides. Large life reinsurers publish underwriting reference material (and individual carriers maintain proprietary impairment manuals) that translate conditions into debits, credits, table ratings, and flat extras. The structure described in §17.3–§17.4 — graded tables, time-graded ratings for treated conditions, flat extras for temporary hazards — is standard industry practice; the specific point values are confidential and vary by insurer.
  • The build-and-blood-pressure tradition. The modern build chart descends from large historical mortality studies relating height, weight, and blood pressure to mortality. The lineage and the use are real; this chapter does not cite specific study figures and you should not either without verifying them.
  • Accelerated-underwriting industry practice. Trade and actuarial literature documents the shift to fluidless, data-driven life underwriting, the use of prescription-history and MIB and MVR data, and the governance debate (random holdouts, back-testing, fairness review). Treat aggregate claims about its prevalence as attributed-but-unverified unless you have the source in hand.
  • The international genetics moratoria/codes. Several countries operate voluntary or statutory limits on life insurers' use of predictive genetic test results below specified coverage thresholds. The existence of such frameworks is real and instructive (Case Study 1); confirm the current specifics for any jurisdiction before relying on them.

Tier 3 — Illustrative / constructed (this chapter)

  • David Okafor — the borderline life applicant (45, \$1M term, mildly elevated cholesterol, BMI 28, father's MI at 58, excellent BP, nonsmoker, cyclist), introduced in Chapter 6 and worked in full here. Constructed teaching example.
  • "Marcus Bell" — the impaired-life table-rating composite of Case Study 2 (controlled diabetes, stented MI four years out, ex-smoker, heavy build). A labeled composite of standard practices.
  • The figures and tables — the table-rating arithmetic (~+25%/table), the mortality-ratio percentages, the evidence-source reconciliation (Figure 17.1), the build-chart contrast (Figure 17.2), the underwriting-depth spectrum, and every dollar amount and premium multiple. All illustrative.

If you read only one thing: read the text of GINA and a plain-language summary of where it does and does not apply — then sit with the gap it leaves in life underwriting. More than any rate table, that gap is where the chapter's hardest question lives: when actuarial fairness (price the risk) and social fairness (do not punish people for their DNA) pull against each other, who decides, and how?